Polyethylene Glycol 400
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Polyethylene Glycol 400: From Constipation and Dry Eye to Bronchitis
One-Sentence Summary
Polyethylene glycol 400 (PEG 400) is a hydrophilic, osmotically active polymer, originally used for constipation and as a lubricant in eye drops for dry eye. The TxGNN model predicts it may be effective for Bronchitis, but the prediction is based on the model alone: 0 clinical trials and 0 publications were found to support it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constipation, dry eye syndrome, xerophthalmia (from the knowledge graph; no approved indication text is available in the US license record) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no active marketing authorization) |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, PEG 400 is a hydrophilic polymer that draws water osmotically. It is used as a laxative and as a lubricant in eye drops, and mechanistically it might be applicable to bronchitis.
One speculative link is airway surface hydration or changes in mucus rheology. No retrieved evidence supports this idea. The high TxGNN score (0.996) is a graph-based prediction and may reflect general network proximity rather than a true pharmacological relationship.
PEG 400 is also mainly used as an excipient or vehicle. This weakens the case for a specific therapeutic effect in bronchitis.
Second predicted indication (for reference): The model also predicted congenital ichthyosiform erythroderma (score 99.10%, also Evidence Level L5, Hold). The speculative rationale is that PEG 400 could act as a humectant or emollient base that hydrates the skin in a hyperkeratotic disorder. This would be supportive and topical at best. It would not address the underlying genetic cause, and no trials or literature were found.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M018 (cancelled) | blink tears (Bausch & Lomb Incorporated) | Solution/drops | Not specified |
Other dosage forms associated with this drug include a solution and a topical gel.
Safety Considerations
The data compiled for this report contain no package insert warnings, contraindications, or drug interaction records for this drug. The knowledge graph does list the following conditions as contraindication-related. These come from a computational graph and are not label text, so they should be verified against the official package insert:
- Cardiovascular and metabolic: hypertension, congestive heart failure, cardiovascular disease, heart disease, diabetes mellitus, hyperglycemia, diabetic ketoacidosis, hypercalcemia, potassium deficiency, phosphorus metabolism disease
- Renal and urinary: kidney disease, anuria, nephrocalcinosis, pyoureter
- Gastrointestinal: ileus, paralytic ileus, intestinal obstruction, toxic megacolon, pyloric stenosis, familial visceral myopathy, appendicitis
- Eye: angle-closure glaucoma, eye infectious disease, conjunctivitis
- Other: epilepsy, hyperthyroidism, Graves disease, thyrotoxicosis
Please refer to the package insert for authoritative safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The bronchitis prediction rests only on a model score, with no clinical trials, no literature, and no documented mechanism of action. PEG 400 is mainly an excipient or vehicle, and its only US authorization has been cancelled. The evidence is not sufficient to justify further development at this time.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank) and a testable hypothesis for airway effects
- Package insert warnings and contraindications from the FDA, to allow safety screening
- Preclinical or literature evidence that PEG 400 affects airway hydration, mucus properties, or inflammation
- Assessment of route compatibility, since an inhaled or oral route for bronchitis has not been evaluated and the existing products are not intended for it
- Assessment of similarity between the original indications and bronchitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.